Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | STS | P08842 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | TACR1 | P25103 | 4/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | APLNR | P35414 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28607570 | 0.84 | TSHR (0.55) | EPHX2TSHRSTSMAPTKMT2A | |
| SCHEMBL28611807 | 0.84 | ALDH1A1 (0.54) | EPHX2TSHRSTSMAPTKMT2A | |
| SCHEMBL27415157 | 0.84 | ALDH1A1 (0.54) | EPHX2TSHRSTSMAPTKMT2A | |
| SCHEMBL4732973 | 0.83 | EPHX2 (0.61) | EPHX2TSHRSTSMAPTKMT2A | |
| SCHEMBL21577641 | 0.78 | EPHX2 (0.57) | EPHX2STSMAPTKMT2AMEN1 | |
| SCHEMBL27415228 | 0.77 | TSHR (0.55) | EPHX2TSHRSTSMAPTKMT2A | |
| SCHEMBL29253172 | 0.76 | STS (0.58) | EPHX2STSMAPTKMT2AMEN1 | |
| SCHEMBL27415267 | 0.76 | EPHX2 (0.46) | EPHX2TSHRSTSMAPTKMT2A | |
| SCHEMBL19331972 | 0.76 | EPHX2 (0.48) | EPHX2TSHRSTSMAPTKMT2A | |
| SCHEMBL31580099 | 0.76 | CD274 (0.57) | EPHX2STSMAPTALDH1A1DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10167283-B2 | β-lactamase inhibitors and uses thereof | SUANZHU PHARMA CO., LTD. (CN) | 2019-01-01 | — | — | US | disclosed |
| US-10167283-B2 | β-lactamase inhibitors and uses thereof | SUANZHU PHARMA CO., LTD. (CN) | 2019-01-01 | — | — | US | disclosed |
| US-20180148448-A1 | ß-LACTAMASE INHIBITORS AND USES THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2018-05-31 | — | — | US | disclosed |
| US-20180148448-A1 | ß-LACTAMASE INHIBITORS AND USES THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2018-05-31 | — | — | US | disclosed |
| US-20180148448-A1 | ß-LACTAMASE INHIBITORS AND USES THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2018-05-31 | — | — | US | disclosed |
| EP-3281942-A1 | B-LACTAMASE INHIBITOR AND APPLICATION THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2018-02-14 | — | — | EP | disclosed |
| EP-3281942-A1 | B-LACTAMASE INHIBITOR AND APPLICATION THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2018-02-14 | — | — | EP | disclosed |
| WO-2017167218-A1 | ANTIBACTERIAL COMPOSITION AND USE THEREOF | 山东轩竹医药科技有限公司 | 2017-10-05 | — | — | WO | disclosed |
| WO-2017045510-A1 | Β-LACTAMASE INHIBITOR AND APPLICATION THEREOF | 山东轩竹医药科技有限公司 | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167283-B2 | β-lactamase inhibitors and uses thereof | MGAM, LCT, ALPI | EPHX2 916/4885TSHR 3985/4885STS 21/4885 |
| US-20180148448-A1 | ß-LACTAMASE INHIBITORS AND USES THEREOF | MGAM, LCT, ALPI | EPHX2 881/4885TSHR 4028/4885STS 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.